The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

被引：263

作者：

Podar, K ^{[1
]}

Anderson, KC ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

BLOOD | 2005年 / 105卷 / 04期

关键词：

D O I：

10.1182/blood-2004-07-2909

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Besides its role as an essential regulator of physiologic and pathologic anglogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopolesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a Potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome. (C) 2005 by The American Society of Hematology.

引用

收藏

页码：1383 / 1395

页数：13

相关论文

共 293 条

[41]

CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017

[42]

Cornali E, 1996, AM J PATHOL, V149, P1851

[43] Interactions of FLT-1 and KDR with phospholipase C gamma: Identification of the phosphotyrosine binding sites [J].

Cunningham, SA ;

Arrate, MP ;

Brock, TA ;

Waxham, MN .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 240 (03) :635-639

[44] SYNTHESIS, ANTITUBULIN AND ANTIMITOTIC ACTIVITY, AND CYTOTOXICITY OF ANALOGS OF 2-METHOXYESTRADIOL, AN ENDOGENOUS MAMMALIAN METABOLITE OF ESTRADIOL THAT INHIBITS TUBULIN POLYMERIZATION BY BINDING TO THE COLCHICINE BINDING-SITE [J].

CUSHMAN, M ;

HE, HM ;

KATZENELLENBOGEN, JA ;

LIN, CM ;

HAMEL, E .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (12) :2041-2049

[45] Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma [J].

D'Amato, RJ ;

Lentzsch, S ;

Anderson, KC ;

Rogers, MS .

SEMINARS IN ONCOLOGY, 2001, 28 (06) :597-601

[46] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[47] CONTROL OF ANGIOGENESIS IN FIBROBLASTS BY P53 REGULATION OF THROMBOSPONDIN-1 [J].

DAMERON, KM ;

VOLPERT, OV ;

TAINSKY, MA ;

BOUCK, N .

SCIENCE, 1994, 265 (5178) :1582-1584

[48] Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines [J].

Damiano, JS ;

Cress, AE ;

Hazlehurst, LA ;

Shtil, AA ;

Dalton, WS .

BLOOD, 1999, 93 (05) :1658-1667

[49] Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma [J].

Dankbar, B ;

Padró, T ;

Leo, R ;

Feldmann, B ;

Kropff, M ;

Mesters, RM ;

Serve, H ;

Berdel, WE ;

Kienast, J .

BLOOD, 2000, 95 (08) :2630-2636

[50] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

← 1 2 3 4 5 6 7 8 9 10 →